Understanding the clinical and biological aspects of monkeypox disease
Official title: Description of the Kinetics of the Clinical and Biological Aspects of the Persons Consulting in the Framework of the Management of the MONKEYPOX Disease
Run by Institut Pasteur · NCT05627713 · Data updated 2026-11-12
This study is trying to learn more about monkeypox by looking at the health and biological details of people who are getting vaccinated or diagnosed with the disease.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 330 (estimated) |
| Sponsor | Institut Pasteur Industry-sponsored |
| Locations | 1 site (Paris) |
| Status | Recruiting |
| Started | December 1, 2022 |
| Main results expected | December 1, 2026 |
| Study ends | December 1, 2026 |
| Registry record updated | December 19, 2023 |
| Trial ID | NCT05627713 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include adults eligible for monkeypox vaccination or suspected of having a monkeypox infection.
✕Probably not a fit
Patients who have already been vaccinated against monkeypox without proof or those with contraindications to vaccination may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study focuses on the clinical and biological characteristics of monkeypox disease, particularly in light of recent outbreaks in non-endemic countries. It is a descriptive, prospective, monocentric, longitudinal study where participants will be enrolled during consultations for vaccination or diagnosis of monkeypox. Data on socio-demographics, clinical status, and treatment will be collected, along with biological samples for various analyses including serological, virological, and genetic studies. The goal is to enhance understanding of the disease and improve management strategies.
Why it matters
Potential benefit: If successful, this study could lead to improved vaccination strategies and better management of monkeypox outbreaks.
How similar studies have gone: Other studies on monkeypox and similar viral infections have shown promise in understanding disease dynamics and improving public health responses.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adult, * eligible for MPXV vaccination according to HAS criteria or suspected of MPXV infection * whose health status is compatible with a 45 ml single blood sample * who have consented to participate in the study * who are covered by a Social Health Insurance plan Exclusion Criteria: * Person with MPXV vaccination without proof of vaccination. * For persons presenting for MPXV vaccination: presence of a contraindication to vaccination other than a current infection. * Pregnant and lactating women * Person unable to give informed consent to participate
Where it's running
-
Centre Médical de l'Institut Pasteur
Paris, France Recruiting
Study contacts
- Principal investigator: Fabien Taieb, MD — Institut Pasteur
- Study coordinator: Fabien Taieb, MD
- Email: fabien.taieb@pasteur.fr
- Phone: + 33(0)1 40 61 38 44
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Neutralizing power of blood and nasal antibodies
This project will test how strong blood and nasal antibodies remain over time in adults getting COVID-19 or monkeypox vaccines or antibody treatments.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.